Apr 6, 2023 7:00 am EDT NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
Mar 16, 2023 7:00 am EDT NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test
Mar 13, 2023 7:00 am EDT NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
Feb 28, 2023 7:00 am EST NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference
Feb 6, 2023 7:00 am EST NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
Feb 6, 2023 7:00 am EST RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
